CD7CAR TGVHDAllogeneic HSCT

Yongxian Hu1, Mingming Zhang1, Tingting Yang1

  • 1From the Bone Marrow Transplantation Center, First Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine (Y.H., M.Z., T.Y., Z.M., G.W., R.J., H.Z., R.C., C.Z., T.G., P.X., R.H., J.F., S.F., D.K., H.X., J.C., S.H., X.Y., H.G., Y.F., C.J., D.W., H.H.), the Institute of Hematology (Y.H., M.Z., T.Y., Z.M., G.W., R.J., H.Z., R.C., C.Z., T.G., P.X., R.H., J.F., S.F., D.K., H.X., J.C., S.H., X.Y., H.G., Y.F., C.J., D.W., H.H.) and the Department of Epidemiology and Statistics, School of Public Health (Y.Y.), Zhejiang University, and Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy (Y.H., M.Z., T.Y., Z.M., G.W., R.J., H.Z., R.C., C.Z., T.G., P.X., R.H., J.F., S.F., D.K., H.X., J.C., S.H., X.Y., H.G., Y.F., C.J., D.W., H.H.), Hangzhou, the Department of Medical Oncology, First Affiliated Hospital of Wenzhou Medical University, Wenzhou (B.L.), the Department of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing (Q.C.), Nanjing Bioheng Biotech, Nanjing (J.R.), and the Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Fudan University, and Shanghai YaKe Biotechnology, Shanghai (A.H.C.) - all in China.

概括

这项研究表明,连续的CD7 CAR T细胞疗法和单一干细胞移植是复发性或耐性CD7阳性白血病和淋巴瘤的安全有效治疗方法. 这种新的方法为那些无法接受传统移植的患者提供了希望.